Beijing Succeeder Technology Inc
Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation testers, platelet aggregation testers, diagnostic reagents, quality control products. Its products are used in the prevention, screening, diagnosis, and… Read more
Beijing Succeeder Technology Inc (688338) - Net Assets
Latest net assets as of September 2025: CN¥1.66 Billion CNY
Based on the latest financial reports, Beijing Succeeder Technology Inc (688338) has net assets worth CN¥1.66 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.75 Billion) and total liabilities (CN¥81.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.66 Billion |
| % of Total Assets | 95.33% |
| Annual Growth Rate | 41.25% |
| 5-Year Change | 21.39% |
| 10-Year Change | N/A |
| Growth Volatility | 82.76 |
Beijing Succeeder Technology Inc - Net Assets Trend (2016–2024)
This chart illustrates how Beijing Succeeder Technology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Succeeder Technology Inc (2016–2024)
The table below shows the annual net assets of Beijing Succeeder Technology Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.65 Billion | +2.87% |
| 2023-12-31 | CN¥1.60 Billion | +6.36% |
| 2022-12-31 | CN¥1.50 Billion | +5.89% |
| 2021-12-31 | CN¥1.42 Billion | +4.77% |
| 2020-12-31 | CN¥1.36 Billion | +261.94% |
| 2019-12-31 | CN¥374.69 Million | +91.51% |
| 2018-12-31 | CN¥195.65 Million | +36.54% |
| 2017-12-31 | CN¥143.30 Million | +37.94% |
| 2016-12-31 | CN¥103.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Succeeder Technology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1754.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥515.08 Million | 31.29% |
| Common Stock | CN¥106.14 Million | 6.45% |
| Other Components | CN¥1.03 Billion | 62.26% |
| Total Equity | CN¥1.65 Billion | 100.00% |
Beijing Succeeder Technology Inc Competitors by Market Cap
The table below lists competitors of Beijing Succeeder Technology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningxia Xiaoming Agriculture & Animal Husbandry Co.Ltd
SHE:300967
|
$205.34 Million |
|
Sinomach General Machinery Science Technology Co Ltd
SHG:600444
|
$205.37 Million |
|
Langfang Development Co Ltd
SHG:600149
|
$205.41 Million |
|
Chularat Hospital Public Company Limited
BK:CHG
|
$205.50 Million |
|
Artius II Acquisition Inc. Units
NASDAQ:AACBU
|
$205.28 Million |
|
Guangdong Jialong Food Co Ltd
SHE:002495
|
$205.27 Million |
|
Momentum Group AB (publ)
ST:MMGR-B
|
$205.25 Million |
|
X-FAB Silicon Foundries SE
PINK:XFABF
|
$205.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Succeeder Technology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,600,247,880 to 1,646,270,295, a change of 46,022,415 (2.9%).
- Net income of 112,999,583 contributed positively to equity growth.
- Dividend payments of 27,597,024 reduced retained earnings.
- Share repurchases of 39,380,144 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥113.00 Million | +6.86% |
| Dividends Paid | CN¥27.60 Million | -1.68% |
| Share Repurchases | CN¥39.38 Million | -2.39% |
| Total Change | CN¥- | 2.88% |
Book Value vs Market Value Analysis
This analysis compares Beijing Succeeder Technology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 22.17x to 2.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.47 | CN¥32.55 | x |
| 2017-12-31 | CN¥1.95 | CN¥32.55 | x |
| 2018-12-31 | CN¥2.65 | CN¥32.55 | x |
| 2019-12-31 | CN¥3.53 | CN¥32.55 | x |
| 2020-12-31 | CN¥12.78 | CN¥32.55 | x |
| 2021-12-31 | CN¥13.39 | CN¥32.55 | x |
| 2022-12-31 | CN¥14.23 | CN¥32.55 | x |
| 2023-12-31 | CN¥15.08 | CN¥32.55 | x |
| 2024-12-31 | CN¥15.59 | CN¥32.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Succeeder Technology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.86%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 36.94%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.06x
- Recent ROE (6.86%) is below the historical average (14.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 29.86% | 24.74% | 0.81x | 1.49x | CN¥20.63 Million |
| 2017 | 20.48% | 18.73% | 0.84x | 1.30x | CN¥15.02 Million |
| 2018 | 28.99% | 28.34% | 0.82x | 1.24x | CN¥37.15 Million |
| 2019 | 18.96% | 30.95% | 0.54x | 1.14x | CN¥33.57 Million |
| 2020 | 5.10% | 31.11% | 0.16x | 1.03x | CN¥-66.43 Million |
| 2021 | 6.85% | 40.58% | 0.16x | 1.04x | CN¥-44.72 Million |
| 2022 | 6.92% | 45.50% | 0.14x | 1.07x | CN¥-46.34 Million |
| 2023 | 7.31% | 42.44% | 0.16x | 1.07x | CN¥-43.11 Million |
| 2024 | 6.86% | 36.94% | 0.17x | 1.06x | CN¥-51.63 Million |
Industry Comparison
This section compares Beijing Succeeder Technology Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Succeeder Technology Inc (688338) | CN¥1.66 Billion | 29.86% | 0.05x | $205.28 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |